Benign Prostatic Hyperplasia Treatment Market Size Share & Report

IMARC Group has recently released a new research study titled “Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2025-2033”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

The global benign prostatic hyperplasia treatment market size was valued at USD 12.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 18.5 Billion by 2033, exhibiting a CAGR of 4.4% during 2025-2033.

Request to Get the Sample Report:

https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market/requestsample

Industry Trends and Drivers:

• Increasing Geriatric Male Population:

The prevalence of benign prostatic hyperplasia (BPH) among geriatric male patients is contributing to the market share. As life expectancy increases globally, the demographic of geriatric men is expanding, leading to a natural rise in the incidence of BPH. This shift drives the demand for effective treatments to manage symptoms like frequent urination, difficulty in starting urination, and incomplete bladder emptying. With more men reaching the age where BPH symptoms become common, healthcare providers are focusing on screening and early intervention. Consequently, these demographic trends have led to substantial market growth, as pharmaceutical companies and medical device manufacturers work to develop targeted therapies.

Additionally, as awareness of BPH increases, men are more likely to seek treatment, increasing market potential further.

• Heightened Awareness and Diagnosis:

Increased awareness about BPH symptoms and the benefits of early diagnosis have played a pivotal role in boosting the market size. Public health initiatives and healthcare campaigns have raised awareness, encouraging men to recognize symptoms early and seek medical advice. Routine health check-ups and prostate screenings have become more common, further aiding in the early diagnosis of BPH. Early diagnosis allows for timely intervention, which can prevent complications and improve quality of life, resulting in a higher demand for BPH treatments.

Furthermore, as healthcare providers and urologists emphasize the importance of managing BPH symptoms proactively, more men are inclined to explore treatment options. This increased awareness has contributed to a positive shift in patient attitudes toward seeking treatment, boosting demand in the BPH treatment market significantly.

• Technological Advancements in Treatment Options:

Medical advancements are transforming the BPH treatment market, with a strong emphasis on minimally invasive procedures and effective pharmaceutical options. Innovations like laser-based therapies, transurethral microwave therapy, and high-intensity focused ultrasound (HIFU) have revolutionized BPH treatment by reducing recovery times and minimizing side effects. These minimally invasive options provide effective symptom relief without the risks associated with traditional surgeries.

Concurrently, pharmaceutical advancements, including alpha-blockers, 5-alpha-reductase inhibitors, and combination therapies, offer alternatives for patients preferring non-surgical treatments. These advancements allow more tailored treatment plans, improving patient outcomes and driving demand.

Benign Prostatic Hyperplasia Treatment Market Report Segmentation:

Breakup By Treatment Type:

• Drug Class

o Alpha-Blockers

o 5-Alpha-reductase Inhibitors (5-ARIs)

o Phosphodiesterase-5 Enzyme Inhibitors

o Others

• Minimally Invasive Surgeries

o Transurethral Resection of the Prostate (TURP)

o Transurethral Incision of the Prostate (TUIP)

o Transurethral Microwave Thermotherapy (TUMT)

o Robotic Surgeries

o Prostatic Urethral Lifts

o Others

• Laser Therapy

• Others

Based on the treatment type, the market has been divided into drug class (alpha-blockers, 5-alpha-reductase inhibitors (5-ARIs), phosphodiesterase-5 enzyme inhibitors, and others), minimally invasive surgeries (transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave therapy (TUMT), robotic surgeries, prostatic urethral lifts, and others), laser therapy, and others.

Breakup By Region:

• North America

• Asia Pacific

• Europe

• Latin America

• Middle East and Africa

Region-wise the market has been segmented into North America (United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa.

Top Benign Prostatic Hyperplasia Treatment Market Leaders:

The benign prostatic hyperplasia treatment market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.

Some of the key players in the market are:

• Abbott Laboratories

• Allergan Plc (AbbVie Inc.)

• Asahi Kasei Corporation

• Astellas Pharma Inc.

• Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)

• Boston Scientific Corporation

• GlaxoSmithKline Plc

• Pfizer Inc.

• Sanofi S.A.

• Teva Pharmaceutical Industries Ltd.

Ask Analyst for Customized Report:

https://www.imarcgroup.com/request?type=report&id=2898&flag=C

Key Highlights of the Report:

• Market Performance (2018-2023)

• Market Outlook (2024-2032)

• Market Trends

• Market Drivers and Success Factors

• Impact of COVID-19

• Value Chain Analysis

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

134 N 4th St

Brooklyn, NY 11249, USA

Website: imarcgroup.com

Email: [email protected]

Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800